BR Biopharma (NASDAQ:BRBI) Stock Keeps "Neutral" Rating at Citigroup

Key Points

• Citigroup reaffirmed its “Neutral” rating on BR Biopharma, while Weiss Ratings modestly upgraded the stock from “Sell (D-)” to “Sell (D).” The overall analyst consensus remains “Reduce,” based on one Hold and one Sell rating.
• BR Biopharma shares fell 7.8% to $9.07, near their 52-week low of $9.08, and remained below both their 50-day and 200-day moving averages.
• The company reported quarterly earnings of $0.09 per share on revenue of $25.13 million. Acuitas Investments also initiated a position by purchasing 3,000 shares worth approximately $45,000.

BR Biopharma (NASDAQ:BRBI - Get Free Report)'s stock had its "neutral" rating reaffirmed by investment analysts at Citigroup in a research report issued on Tuesday, Benzinga reports.

Separately, Weiss Ratings raised shares of BR Biopharma from a "sell (d-)" rating to a "sell (d)" rating in a report on Friday, October 2nd. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, BR Biopharma has an average rating of "Reduce".

BR Biopharma Stock Down 7.8%

BRBI traded down $0.77 during midday trading on Tuesday, reaching $9.07. The company had a trading volume of 11,343 shares, compared to its average volume of 3,461. The business has a 50-day moving average of $11.85 and a two-hundred day moving average of $12.85. The company has a market cap of $107.12 million and a P/E ratio of 113.38. BR Biopharma has a 1 year low of $9.08 and a 1 year high of $16.61.

BR Biopharma (NASDAQ:BRBI - Get Free Report) last posted its quarterly earnings data on Tuesday, June 30th. The company reported $0.09 earnings per share for the quarter. The company had revenue of $25.13 million for the quarter.

Institutional Investors Weigh In On BR Biopharma

An institutional investor recently bought a new position in BR Biopharma stock. Acuitas Investments LLC purchased a new stake in shares of BR Biopharma, Inc. (NASDAQ:BRBI - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 3,000 shares of the company's stock, valued at approximately $45,000. BR Biopharma accounts for about 3.2% of Acuitas Investments LLC's portfolio, making the stock its 7th biggest position.

BR Biopharma Company Profile

BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.